Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER
Author:
E. Smyth,D. Griffiths,K. Cozens,S. Ewings,R. Waugh,R.C. Turkington,K. Foley,R. Roy,S. Ngan,R. Owen,D. Chuter,C. Steele,G. Griffiths
Publication:
ESMO Gastrointestinal Oncology
© 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.